NASDAQ:DVAX Dynavax Technologies - DVAX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. $9.96 +0.09 (+0.91%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$9.79▼$10.0550-Day Range$9.44▼$11.8852-Week Range$7.26▼$17.48Volume1.21 million shsAverage Volume1.54 million shsMarket Capitalization$1.27 billionP/E Ratio5.06Dividend YieldN/APrice Target$24.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Dynavax Technologies MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside144.3% Upside$24.33 Price TargetShort InterestBearish12.66% of Shares Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$232,211 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.50) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.53 out of 5 starsMedical Sector126th out of 983 stocksPharmaceutical Preparations Industry45th out of 478 stocks 3.5 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.33, Dynavax Technologies has a forecasted upside of 144.3% from its current price of $9.96.Amount of Analyst CoverageDynavax Technologies has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.66% of the outstanding shares of Dynavax Technologies have been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Dynavax Technologies has recently decreased by 13.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Dynavax Technologies is -1.59. Previous Next 1.9 News and Social Media Coverage News SentimentDynavax Technologies has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Dynavax Technologies this week, compared to 2 articles on an average week.Search Interest65 people have searched for DVAX on MarketBeat in the last 30 days. This is an increase of 306% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,211.00 in company stock.Percentage Held by InsidersOnly 9.31% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions94.26% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to grow in the coming year, from ($0.50) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is 5.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is 5.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.36.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dynavax Technologies (NASDAQ:DVAX) StockDynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.Read More Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DVAX Stock News HeadlinesMarch 19, 2023 | finance.yahoo.comDynavax Technologies Corporation (NASDAQ:DVAX) Could Be Riskier Than It LooksMarch 1, 2023 | finance.yahoo.comDynavax to Present at the Cowen 43rd Annual Health Care ConferenceMarch 21, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 1, 2023 | msn.comDynavax Technologies's Return On Capital Employed InsightsFebruary 28, 2023 | markets.businessinsider.comDynavax Gets Great Britain Marketing Authorization For Hepatitis B Vaccine Heplisav BFebruary 28, 2023 | finance.yahoo.comDynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted VaccineFebruary 26, 2023 | finance.yahoo.comNeed To Know: Analysts Just Made A Substantial Cut To Their Dynavax Technologies Corporation (NASDAQ:DVAX) EstimatesFebruary 25, 2023 | seekingalpha.comDynavax Technologies Corporation (DVAX) Q4 2022 Earnings Call TranscriptMarch 21, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 24, 2023 | msn.comJMP Securities Maintains Market Outperform Rating for Dynavax Technologies: Here's What You Need To KnowFebruary 24, 2023 | finance.yahoo.comHere Are 3 Healthcare Stocks That DeliverFebruary 24, 2023 | finance.yahoo.comQ4 2022 Dynavax Technologies Corp Earnings CallFebruary 24, 2023 | finanznachrichten.deDynavax Technologies: Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial GuidanceFebruary 23, 2023 | finance.yahoo.comDynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial GuidanceFebruary 17, 2023 | finance.yahoo.comDynavax Technologies Corporation's (NASDAQ:DVAX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?February 16, 2023 | finance.yahoo.comWall Street Analysts See a 109.61% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?February 13, 2023 | finance.yahoo.comBlueprint's (BPMC) Cancer Study Put on Partial Hold by FDAFebruary 9, 2023 | finance.yahoo.comDynavax to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023February 8, 2023 | finance.yahoo.comDynavax Technologies (DVAX) Upgraded to Strong Buy: Here's What You Should KnowJanuary 31, 2023 | finance.yahoo.comDynavax Announces Uplisting to the Nasdaq Global Select MarketJanuary 26, 2023 | finance.yahoo.comWall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 103.22%: Read This Before Placing a BetJanuary 16, 2023 | reuters.comDVAX.OQ - | Stock Price & Latest News | ReutersJanuary 15, 2023 | finance.yahoo.comClover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023January 9, 2023 | finance.yahoo.comDynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline ResultsJanuary 5, 2023 | thestreet.comDynavax Stock Gaps Down On Today's Open (DVAX)December 18, 2022 | finance.yahoo.comI'm Going to Give This Biotech Another ShotNovember 9, 2022 | finance.yahoo.comDynavax to Present at Two Upcoming Investor ConferencesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DVAX Company Calendar Last Earnings11/04/2021Today3/21/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:DVAX CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees311Year Founded1996Price Target and Rating Average Stock Price Forecast$24.33 High Stock Price Forecast$27.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+144.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.97 Trailing P/E Ratio5.06 Forward P/E RatioN/A P/E GrowthN/ANet Income$293.16 million Net Margins40.56% Pretax Margin40.72% Return on Equity65.26% Return on Assets29.11% Debt Debt-to-Equity Ratio0.38 Current Ratio6.11 Quick Ratio5.71 Sales & Book Value Annual Sales$722.68 million Price / Sales1.76 Cash Flow$2.45 per share Price / Cash Flow4.07 Book Value$4.55 per share Price / Book2.19Miscellaneous Outstanding Shares127,690,000Free Float115,799,000Market Cap$1.27 billion OptionableOptionable Beta1.45 Social Links Key ExecutivesRyan SpencerChief Executive Officer & DirectorDavid F. NovackPresident & Chief Operating OfficerKelly MacDonaldChief Financial Officer & Senior Vice PresidentRobert JanssenChief Medical Officer & SVP-Clinical DevelopmentTodd LopemanVice President-Technical OperationsKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDMannKindNASDAQ:MNKDOPKO HealthNASDAQ:OPKGeronNASDAQ:GERNImmunoGenNASDAQ:IMGNView All CompetitorsInsiders & InstitutionsJustin BurgessSold 22,371 sharesTotal: $232,210.98 ($10.38/share)Teachers Retirement System of The State of KentuckyBought 6,883 shares on 2/22/2023Ownership: 0.028%Macquarie Group Ltd.Sold 1,006 shares on 2/21/2023Ownership: 0.596%State of WyomingBought 12,011 shares on 2/16/2023Ownership: 0.016%Point72 Middle East FZEBought 4,995 shares on 2/16/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions DVAX Stock - Frequently Asked Questions Should I buy or sell Dynavax Technologies stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DVAX shares. View DVAX analyst ratings or view top-rated stocks. What is Dynavax Technologies' stock price forecast for 2023? 3 analysts have issued 1 year price objectives for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $27.00. On average, they predict the company's stock price to reach $24.33 in the next year. This suggests a possible upside of 144.3% from the stock's current price. View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts. How have DVAX shares performed in 2023? Dynavax Technologies' stock was trading at $10.64 at the beginning of the year. Since then, DVAX stock has decreased by 6.4% and is now trading at $9.96. View the best growth stocks for 2023 here. Are investors shorting Dynavax Technologies? Dynavax Technologies saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 16,160,000 shares, a decrease of 13.3% from the February 13th total of 18,640,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is currently 10.0 days. View Dynavax Technologies' Short Interest. When is Dynavax Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our DVAX earnings forecast. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company had revenue of $108.27 million for the quarter, compared to analyst estimates of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 65.26% and a net margin of 40.56%. During the same quarter in the previous year, the business earned ($0.15) EPS. What ETFs hold Dynavax Technologies' stock? ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco S&P SmallCap Health Care ETF (PSCH), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Franklin Genomic Advancements ETF (HELX). What is Eddie Gray's approval rating as Dynavax Technologies' CEO? 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). What is Dynavax Technologies' stock symbol? Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX." Who are Dynavax Technologies' major shareholders? Dynavax Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Chicago Capital LLC (4.59%), Fisher Asset Management LLC (3.20%), Blair William & Co. IL (1.95%), Geode Capital Management LLC (1.74%), Morgan Stanley (1.60%) and Dimensional Fund Advisors LP (1.40%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dynavax Technologies' stock price today? One share of DVAX stock can currently be purchased for approximately $9.96. How much money does Dynavax Technologies make? Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.27 billion and generates $722.68 million in revenue each year. The biopharmaceutical company earns $293.16 million in net income (profit) each year or $1.97 on an earnings per share basis. How many employees does Dynavax Technologies have? The company employs 311 workers across the globe. How can I contact Dynavax Technologies? Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327. This page (NASDAQ:DVAX) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.